GoodRx
GoodRx is a technology company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at GoodRx.
GoodRx is a technology company.
Key people at GoodRx.
GoodRx is a digital healthcare platform that provides price comparison tools for prescription drugs, enabling consumers to find discounts and savings at pharmacies nationwide, alongside telehealth services and lab testing. It serves millions of individual consumers, healthcare professionals, employers, and health plans, addressing the lack of transparency and high costs in the U.S. pharmaceutical market by aggregating pricing data and offering up to 80% savings on medications.[1][2][4] In 2024, GoodRx reached nearly 30 million unique consumers and facilitated almost $17 billion in savings, demonstrating strong growth momentum through expansions into telehealth and strategic acquisitions like ScriptCycle and vitaCare.[1][3]
The company's mission is to help Americans get the healthcare they need at a price they can afford, empowering informed decisions via transparent pricing and comprehensive services.[1][4][7]
GoodRx was founded in 2011 by Doug Hirsch, Trevor Bezdek, and Scott Marlette, driven by Hirsch's personal experience of discovering wildly varying prescription prices—$450 at one pharmacy, $250 at another—despite having insurance, highlighting the opacity in drug pricing.[2][4][5] The idea emerged to create a platform for comparing prices online, akin to other consumer goods, solving affordability and transparency issues for insured and uninsured Americans alike.[1][4]
Early traction came quickly: by 2015, it hit 1 million monthly users, validating demand for its discount coupons from thousands of pharmacies.[1] Pivotal moments include expanding into telehealth for same-day virtual consultations and at-home lab tests, plus acquisitions that broadened its reach into prescription fulfillment and pharmacy networks.[1][2][3]
GoodRx rides the wave of digital health disruption in a $500+ billion U.S. pharmaceutical market plagued by opaque pricing and high costs, timing its launch amid rising drug expenses and consumer demand for transparency post-2010s healthcare reforms.[1][3] Favorable market forces include pharmacy benefit managers' dominance, insurance gaps affecting millions, and telehealth acceleration from the COVID-19 pandemic, enabling GoodRx to capture share via tech scalability.[2][4]
It influences the ecosystem by fostering competition among pharmacies, pressuring price reductions, and setting standards for consumer-facing health tech, while partnering with employers and plans to integrate savings into broader benefits.[1][6]
GoodRx is poised to deepen its platform with more telehealth features, AI-driven personalization, and expanded services like chronic care management, capitalizing on trends in value-based care and regulatory pushes for drug price transparency.[3] Evolving market dynamics—such as biosimilar adoption and potential policy reforms—could amplify savings, though competition from pharmacy chains and PBMs poses risks; its public status (NASDAQ: GDRX) with a forward P/E of 34.05 signals investor confidence in sustained growth.[5]
As a pioneer in affordable healthcare tech, GoodRx continues transforming access, anchoring its strategy on the belief that transparency lowers costs for every American.[1]
Key people at GoodRx.